

1 **Supplemental methods**

2

3 **TMT-proteomics**

4 Brains of mice at PND15 were extracted, rapidly embedded in Tissue-Tek O.C.T compound
5 (Sakura Finetek) and frozen in a -50°C isopentane solution (Fisher Scientific). Frozen tissue
6 punches were extracted through the ARC with a 1 mm diameter cannula as described above and
7 stored at -80°C until use. Samples were processed using the streamlined TMT labelling protocol
8 (1). Samples were lysed in 8 M urea in 200 mM EPPS pH 8.5 with protease (Pierce A32953) and
9 phosphatase (Pierce A32957) inhibitors and passed through a 21-gauge needle 10x. Samples were
10 reduced with 5 mM TCEP, alkylated with 10 mM iodoacetamide, and quenched with 5 mM DTT,
11 followed by methanol/chloroform precipitation of 100 µg. Pellets were reconstituted in 200 mM
12 EPPS pH 8.5, digested overnight with LysC (Wako 129-02541) at 1:100 while shaking at room
13 temperature, followed by digestion with trypsin (Pierce 90305) at 1:100 while shaking at 37°C.
14 Anhydrous acetonitrile (Honeywell AS017-0100) was added to ~30%, followed by labelling with
15 TMT11 (Thermo A37727) reagent. 1% of each labeled sample was combined and analyzed
16 unfractionated to ensure labeling efficiency was >97% and that the samples are mixed at a 1:1
17 (total amount) ratio across all conditions. After mixing, labelled peptide samples were de-salted
18 using a 100 mg Sep-Pak cartridge (Waters WAT054925), followed by drying in a rotary
19 evaporator. Samples were then reconstituted in 5% ACN 10 mM ammonium bicarbonate for basic
20 reverse phase fractionation on an Agilent 300extend-C18 column (3.5µm, 4.6x250mm) using an
21 Agilent Infinity 1260 HPLC. Peptides were subjected to a 75 min linear gradient from 13% to 42%
22 of Buffer B (10 mM ammonium bicarbonate, 90% ACN, pH 8) at a flow rate of 0.6 mL/min,
23 resulting in a total of 96 fractions which were consolidated into 24 by combining (in a chessboard

24 pattern) four alternating wells down columns of the 96-well plate. Assuming adjacent fractions
25 contain overlapping peaks, only 12 non-adjacent samples were analyzed by the mass spectrometer.
26 The pooling scheme has been illustrated previously (1, 2). Each eluted fraction was desalted via
27 StageTip for SPS-MS3 analysis.

28 Mass spectra were collected on Orbitrap Fusion mass spectrometer (ThermoFisher
29 Scientific) coupled to a Proxeon EASY-nLC 1200 LC pump (ThermoFisher Scientific). Peptides
30 were separated on a 35 cm column (i.d. 100 μm , Accucore, 2.6 μm , 150 \AA) packed in-house using
31 a 150 min gradient (from 5% -30% acetonitrile with 0.1% formic acid) at 500 nl/min. Each analysis
32 used an SPS-MS3-based TMT method (3, 4). MS1 data were collected using the Orbitrap (120,000
33 resolution; maximum injection time 50 ms; AGC 4e5, 400-1400 m/z). Determined charge states
34 between 2 and 5 were required for sequencing and a 90 s dynamic exclusion window was used.
35 MS2 scans consisted of collision-induced dissociation (CID), quadrupole ion trap analysis,
36 automatic gain control (AGC) 2E4, NCE (normalized collision energy) 34, q-value 0.25,
37 maximum injection time 35 ms, and isolation window of 0.7 Da using a Top10 method.

38 Mass spectra were processed using a COMET-based software pipeline. Data were searched
39 against the UniProt Mouse database (April 2019), using a 20-ppm precursor ion tolerance for total
40 protein-level analysis, 1.0005 Da product ion tolerance, and 0.4 Da fragment bin offset. TMT tags
41 on lysine residues and peptide N termini (11-plex: +229.163 Da) and carbamidomethylation of
42 cysteine residues (+57.021 Da) were set as static modifications, while oxidation of methionine
43 residues (+15.995 Da), and deamidation of N and Q (-0.984 Da) were set as variable modifications.
44 Peptide-spectrum matches (PSMs) were identified, quantified, and filtered to a 1% peptide false
45 discovery rate (FDR) and then collapsed further to a final protein-level FDR of 1%. Proteins were
46 quantified by summing reporter ion counts across all matching PSMs. Briefly, a 0.003 Da (3


47 millidalton) window around the theoretical m/z of each reporter ion was scanned and the maximum
48 intensity nearest the theoretical m/z was used. Reporter ion intensities were adjusted to correct for
49 the isotopic impurities of the different TMT reagents according to manufacturer specifications and
50 adjusted to normalize ratios across labelling channels. Lastly, for each protein, signal-to-noise
51 (S:N) measurements of the peptides were summed and then normalized to 100. The mass
52 spectrometry proteomics data are available in Suppl. Table 3. They also have been deposited to
53 the ProteomeXchange Consortium via the PRIDE partner repository with the dataset
54 identifier PXD027220 (5).

55


- 56 1. Navarrete-Perea J, Yu Q, Gygi SP, Paulo JA. Streamlined Tandem Mass Tag (SL-TMT)
57 Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling Using Tandem
58 Mass Tag-Synchronous Precursor Selection-MS3. *J. Proteome Res.* 2018;17(6):2226–2236.
- 59 2. Paulo JA et al. Quantitative mass spectrometry-based multiplexing compares the abundance of
60 5000 *S. cerevisiae* proteins across 10 carbon sources. *J. Proteomics* 2016;148:85–93.
- 61 3. McAlister GC et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of
62 differential expression across cancer cell line proteomes. *Anal. Chem.* 2014;86(14):7150–7158.
- 63 4. Ting L, Rad R, Gygi SP, Haas W. MS3 eliminates ratio distortion in isobaric multiplexed
64 quantitative proteomics. *Nat. Methods* 2011;8(11):937–940.
- 65 5. Perez-Riverol Y et al. The PRIDE database and related tools and resources in 2019: improving
66 support for quantification data. *Nucleic Acids Res.* 2019;47(D1):D442–D450.

67


68 **Supplementary figures**



69 **Supplementary figure 1. Generation of *MKRN3*-WT and *MKRN3*-KO hiPSC-derived**
 70 **hypothalamic ARC neurons.** (A, B) Sanger sequencing of the two bi-allelic *MKRN3*-KO hiPSC
 71 clones showing the introduction of (A) a 5 bp deletion and a 7 bp deletion in the *MKRN3*-KO 1
 72 and (B) a 117 bp deletion and a 1 bp insertion in the *MKRN3*-KO 2 hiPSCs, using CRISPR/Cas9
 73 technology. (C-J) *MKRN3* (C), *OCT4* (D), *NKX2.1* (E), *NESTIN* (F), *MAP2* (G), *POMC* (H),
 74 *KISS1* (I) and *TAC3* (J) mRNA levels in hiPSCs, NPCs and hypothalamic ARC neurons derived
 75 from the *MKRN3*-WT 2 and *MKRN3*-KO 2 clones (n = 3 differentiation protocols per group),
 76 relative to levels in *MKRN3*-WT 2 NPCs. Data are presented as the mean ± SEM values. Statistics
 77 were performed using two-way ANOVA, followed by Tukey post-hoc test. * $p < 0.01$.



78 **Supplementary figure 2. *Mkrn3* is maternally imprinted and expressed only from the**
 79 **paternal allele in the mouse hypothalamus.** (A) Relative *Mkrn3* mRNA levels in the
 80 hypothalamus of *Mkrn3*^{+/+} (wild-type) and *Mkrn3*^{+/-} (deletion originated from the paternal allele)
 81 mice at postnatal day 10 (n = 3 per genotype). (B) Relative *Mkrn3* mRNA levels in the
 82 hypothalamus of *Mkrn3*^{+/+} (wild-type) and *Mkrn3*^{-/+} (deletion originated from the maternal allele)
 83 mice at postnatal day 10 (n = 3-4 per genotype). Statistics were performed using unpaired two-
 84 tailed *t*-test. Data are presented as the mean ± SEM values. **p < 0.01 compared to *Mkrn3*^{+/+}.



85 **Supplementary figure 3. *Mkrn3* deletion does not modify adult female cyclicity.** (A) Average
 86 length of the estrous cycle in *Mkrn3*^{KO} females compared to *Mkrn3*^{WT} (n = 6 per genotype).
 87 Statistics were performed using unpaired two-tailed *t*-test ($t_{(10)} = 0.161$, $p = 0.875$). (B) Average
 88 amount of time spent in each stage of the estrous cycle in *Mkrn3*^{WT} and *Mkrn3*^{KO} females (n = 6
 89 per genotype). Statistics were performed using two-way ANOVA, followed by Tukey post-hoc
 90 test (genotype effect: $F_{(1,30)} = 0.002$, $p = 0.956$). Data are presented as the mean \pm SEM values.

91 **Supplementary Tables**

92 **Supplementary Table 1.** Fertility analysis of *Mkrm3*^{WT} and *Mkrm3*^{KO} mice.

	Female		Male	
	<i>Mkrm3</i> ^{WT}	<i>Mkrm3</i> ^{KO}	<i>Mkrm3</i> ^{WT}	<i>Mkrm3</i> ^{KO}
Time to first litter (days)	23.3 ± 0.3	26.3 ± 1.9	23.3 ± 0.3	26.3 ± 3.3
Number of litters	3.7 ± 0.3	4.0 ± 0.6	3.7 ± 0.3	4.0 ± 0.0
Number of pups per litter	5.00 ± 0.3	5.6 ± 0.6	5.00 ± 0.3	5.00 ± 0.5
Total number of pups	18.3 ± 2.3	20.3 ± 1.5	18.3 ± 2.3	19.7 ± 1.86

93

94 During 4 months of continuous mating, *Mkrm3*^{WT} and *Mkrm3*^{KO} males and females produced
 95 offspring with the same time to first litter (Female: $t_{(4)} = 1.591$, $p = 0.187$; Male: $t_{(4)} = 0.896$, $p =$
 96 0.421), comparable numbers of litters (Female: $t_{(4)} = 0.500$, $p = 0.643$; Male: $t_{(4)} = 1.000$, $p =$
 97 0.374), and comparable litter size (Female: $t_{(4)} = 0.977$, $p = 0.384$; Male: $t_{(4)} = 0.106$, $p = 0.921$),
 98 as well as total number of pups (Female: $t_{(4)} = 0.728$, $p = 0.507$; Male: $t_{(4)} = 0.447$, $p = 0.678$).
 99 Statistics were performed using unpaired two-tailed *t*-test.

100

101 **Supplementary Table 2.** Primers used for RT-qPCR and PCR.

Gene	NCBI Reference Sequence	Forward primer	Reverse primer
CRISPR-Cas9 targeting			
<i>MKRN3 gRNA</i>	--	TTTCTTGGCTTTATATATCTTGTGGAA AGGACGAAACACCGCCAGCCCCTTG CCGCATG	GACTAGCCTTATTTTAACTTGCTATTT CTAGCTCTAAAACCATGCGGCAAGGG GCTGGGC
RT-qPCR - Human			
<i>MKRN3 del1</i>	NM_005664.4	ATTCAGCCCTGCCACATGCG	CTTCGGCTTGGCAACGGAC
<i>MKRN3 del2</i>	NM_005664.4	ATTCAGCCCTGCCACATGCG	GTCGTGCGAATAGCGACAGT
<i>OCT4</i>	NM_002701.6	GGTTCTATTTGGGAAGGTATTCAG	GGTTCGCTTTCTCTTTTCGG
<i>NKX2-1</i>	NM_001079668.3	CAGGACACCATGAGGAACAGCG	GCCATGTTCTTGCTCACGTCCC
<i>NESTIN</i>	NM_006617.2	GGCGCACCTCAAGATGTCC	CTTGGGGTCTGAAAGCTG
<i>MAP2</i>	NM_002374.4	TAACCAACCACTGCCAGACCTGAA	GCCACATTTGGATGTCACATGGCT
<i>POMC</i>	NM_001035256.3	CTGGAGAGCAGCCAGTGTCAG	AGAGGCTGCTCGTCGCCATTTTC
<i>KISS1</i>	NM_002256.4	GCACTTCTAGGACCTGCCTC	GATTCTAGCTGCTGGCCTGTG
<i>TAC3</i>	NM_013251.4	CAAAGCCACTCATCTCTGGAGG	GTCCTCTTGCCATAAGTCCC
<i>SLIT1</i>	NM_003061.3	CTCCTTCACCAACATGAGCCAG	AGGGTGGAGATGTCATTGCCGT
<i>SLIT2</i>	NM_004787.4	CAGAGCTTCAGCAACATGACCC	GAAAGCACCTTCAGGCACAACAG
<i>NRCAM</i>	NM_001037132.4	TGTGGCTGAAGGACAACAGGGA	AGACGCTGTCCAGAGTGGTGT
RT-qPCR - Mouse			
<i>Mkrm3</i>	NM_011746.3	AAGCGCATACTGGCATCAAG	AGCCAACGGTCATCAGAGAA
<i>Kiss1</i>	NM_178260.3	GCTGCTGCTTCTCCTCTGTG	TCTGCATACCGGATTCTT
<i>Kiss1r</i>	NM_053244.5	GGTGCTGGGAGACTTCATGT	ACATACCAGCGGTCCACACT
<i>Gnrh</i>	NM_008145.3	GGGAAAGAGAAACACTGAACAC	GGACAGTACATTGGAAGTGCT
<i>Tac3</i>	NM_009312.2	GCTCCACAGCTTTGTCCTTC	GCTAGCCTTGCTCAGCACTT
<i>Tac1</i>	NM_009311.3	ACCAGATCAAGGAGGCAATG	AGCCTTTAACAGGGCCACTT
PCR - Mouse			
<i>Mkrm3-WT</i>		GCCATATGCTCTCTCAATTGCCG	AATTTGTTCTTGACAGCCTTACCG
<i>LacZ marker</i>		ACTTGCTTTAAAAACCTCCCACA	ACATGTAAACAAACACAGACAGCAGC

102